Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores via targeting glycerophospholipid and fatty acid Metabolism

ABSTRACT: Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores via targeting glycerophospholipid and fatty acid Metabolism

PROVIDER: PRJNA1163013 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Multi-omics analysis reveals inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores via targeting glycerophospholipid and fatty acid Metabolism

Project description:Osteosarcoma (OS) is a severe malignancy affecting children and adolescents, with limited effective treatments leading to poor outcomes. This study explored the potential of sporoderm-removed Ganoderma lucidum spores (RGLS) as a novel therapeutic agent against OS and elucidated its mechanism of action. Our in vivo and in vitro experiments showed that RGLS significantly inhibited S-180 OS cell proliferation, colony formation, and migration, while simultaneously inducing apoptosis. Multi-omics analysis revealed that RGLS disrupted glycerophospholipid metabolism by upregulating lysophosphatidylcholine (LysoPC) levels through phospholipase A2 (PLA2)-mediated pathways. Co-culture assays further demonstrated that RGLS promoted the endocytosis of macrophage-derived Pla2g7 protein into S-180 cells, enhancing its anti-cancer effects. Additionally, RGLS modulated the cellular fatty acid profile and suppressed the β-oxidation of long-chain fatty acids, leading to energy depletion in OS cells. These findings provide a novel view of the multi-targeted mechanisms of RGLS, positioning it as a promising candidate for OS therapy.

2025-07-09 | GSE277633 | GEO

Inhibition of osteosarcoma progression by sporoderm-removed ganoderma lucidum spores

2024-09-25 | PXD056264 |

Protective effects of Ganoderma lucidum spores on estradiol benzoate-induced TEC apoptosis and compromised double-positive thymocyte development

Project description:Thymic atrophy is the initial event of immune aging and leads to developmental disorders of T cell . Invariant natural killer T (iNKT) cells are a distinctive subset of innate-like T cells, which are involved in the occurrence and development of various diseases, such as tumor, obesity and diabetes. Cell therapy targeting iNKT cells has become an emerging therapy after PD-1/PD-L1, CTLA-4 and CAR-T therapy. However, the scarcity of iNKT cells in the body limits its application in clinical therapy. A large number of clinical studies and preclinical studies have demonstrated that Ganoderma lucidum spores (GLS) regulates traditional T cell development. Nevertheless, whether GLS regulates iNKT cell development and its underlying mechanisms remains unknown.

2024-09-09 | GSE253901 | GEO

Ganoderma lucidum

Project description:Ganoderma lucidum Transcriptome

| PRJNA736534 | ENA

Ganoderma lucidum

Project description:Ganoderma lucidum Metagenome

| PRJNA389612 | ENA

Ganoderma lucidum

Project description:Ganoderma lucidum' substrate Metagenome

| PRJNA392763 | ENA

Ganoderma lucidum

Project description:Ganoderma lucidum Genome sequencing